Mutagenesis of key residues in these regions impairs TR4’s interactions and transcriptional activation across experimental models [29,129], providing a structural blueprint for the therapeutic targeting of TR4-associated diseases, including erythroid disorders, diabetes, and malignancies [130]. Here, NR2C2 is linked to cancer.